カテゴリー： 世界, 医療/バイオ, Market Monitor Global

世界のDTaP＆Tdapワクチン市場予測2023-2029：DTaP、Td、Tdap

【英語タイトル】DTaP and Tdap Vaccines Market, Global Outlook and Forecast 2023-2029

Market Monitor Globalが出版した調査資料（MMG23LY8501）・商品コード：MMG23LY8501
・発行会社（調査会社）：Market Monitor Global
・発行日：2023年7月
・ページ数：77
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後2-3営業日）
・調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど
・産業分野：医薬品＆ヘルスケア
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,250 ⇒換算￥494,000見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD4,225 ⇒換算￥642,200見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）USD4,875 ⇒換算￥741,000見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
❖ レポートの概要 ❖

当調査レポートは次の情報を含め、世界のDTaP＆Tdapワクチン市場規模と予測を収録しています。・世界のDTaP＆Tdapワクチン市場：売上、2018年-2023年、2024年-2029年
・世界のDTaP＆Tdapワクチン市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界のDTaP＆Tdapワクチン市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「DTaP」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。

DTaP＆Tdapワクチンのグローバル主要企業は、Sanofi Pasteur、 GlaxoSmithKline、 Protein Sciences Corporation、 Novartis AG、 Seqirus、 Merck Sharp & Dohme Corp、 Astellas Pharma US, Inc、 Pfizer Inc、 Johnson & Johnson、 Lanzhou Institute of Biological Products Co., Ltd、 AstraZeneca、 Emergent BioSolutions Incなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

MARKET MONITOR GLOBAL（MMG）は、DTaP＆Tdapワクチンのメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別市場分析】

世界のDTaP＆Tdapワクチン市場：タイプ別、2018年-2023年、2024年-2029年
世界のDTaP＆Tdapワクチン市場：タイプ別市場シェア、2022年
・DTaP、Td、Tdap

世界のDTaP＆Tdapワクチン市場：用途別、2018年-2023年、2024年-2029年
世界のDTaP＆Tdapワクチン市場：用途別市場シェア、2022年
・成人、小児

世界のDTaP＆Tdapワクチン市場：地域・国別、2018年-2023年、2024年-2029年
世界のDTaP＆Tdapワクチン市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競合分析】

また、当レポートは主要な市場参加者の分析を提供します。
・主要企業におけるDTaP＆Tdapワクチンのグローバル売上、2018年-2023年
・主要企業におけるDTaP＆Tdapワクチンのグローバル売上シェア、2022年
・主要企業におけるDTaP＆Tdapワクチンのグローバル販売量、2018年-2023年
・主要企業におけるDTaP＆Tdapワクチンのグローバル販売量シェア、2022年

さらに、当レポートは主要企業のプロファイルを提示します。
Sanofi Pasteur、 GlaxoSmithKline、 Protein Sciences Corporation、 Novartis AG、 Seqirus、 Merck Sharp & Dohme Corp、 Astellas Pharma US, Inc、 Pfizer Inc、 Johnson & Johnson、 Lanzhou Institute of Biological Products Co., Ltd、 AstraZeneca、 Emergent BioSolutions Inc

*************************************************************

・調査・分析レポートの概要
DTaP＆Tdapワクチン市場の定義
市場セグメント
世界のDTaP＆Tdapワクチン市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界のDTaP＆Tdapワクチン市場規模
世界のDTaP＆Tdapワクチン市場規模：2022年 VS 2029年
世界のDTaP＆Tdapワクチン市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでのDTaP＆Tdapワクチンの売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業のDTaP＆Tdapワクチン製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：DTaP、Td、Tdap
DTaP＆Tdapワクチンのタイプ別グローバル売上・予測

・用途別市場分析
用途区分：成人、小児
DTaP＆Tdapワクチンの用途別グローバル売上・予測

・地域別市場分析
地域別DTaP＆Tdapワクチン市場規模 2022年と2029年
地域別DTaP＆Tdapワクチン売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど）
Sanofi Pasteur、 GlaxoSmithKline、 Protein Sciences Corporation、 Novartis AG、 Seqirus、 Merck Sharp & Dohme Corp、 Astellas Pharma US, Inc、 Pfizer Inc、 Johnson & Johnson、 Lanzhou Institute of Biological Products Co., Ltd、 AstraZeneca、 Emergent BioSolutions Inc
...

Pertussis vaccine is used for whooping cough. This vaccine is available only in combination with other vaccines. Pertussis vaccination is recommended for all children, babies, teens, and pregnant women. Diphtheria, tetanus, and pertussis (DTaP) vaccines are given to children younger than seven years old, while tetanus, diphtheria, and pertussis (Tdap) vaccines are given to older children and adults. Childhood vaccination is one of the safest and cost-effective ways for pertussis-free environment. The World Health Organization (WHO) and Centers for Disease Control and Prevention (CDC) recommend all children should be routinely vaccinated for pertussis. According to WHO in 2015, about 86% of infants received three doses of diphtheria-tetanus-pertussis (DTP3) vaccine worldwide to protect them against infectious diseases. In 2015, procurement of DTwP vaccine through UNICEF had reached 5.8 million doses for 18 countries and territories out of which four countries such as Egypt, Morocco, Uzbekistan, and Zimbabwe accounted for more than 80% of UNICEF’s total procurement.

Factors such as high birth rate, increase in number of geriatric population, government initiatives, growth in adoption of pertussis vaccination, and government insurance and reimbursement scenario are projected to drive the pertussis vaccine market globally. According to WHO in 2015, 126 countries had reached at least 90% coverage of diphtheria-tetanus-pertussis vaccine. On the other hand, factors such as vaccine injuries and adverse event are expected to hinder the growth of the pertussis vaccine market globally. In the U.S. in 2015, there had been 7 claims filed in the federal Vaccine Injury Compensation Program (VICP) for injuries and deaths following pertussis vaccination, including three deaths and four serious injuries.

The pertussis vaccine market has been segmented by product type, vaccine type, age group, end-user, and geography. In terms of product type, the pertussis vaccine market is classified into DTaP vaccine and Tdap vaccine. The DTaP vaccine segment includes products such as Daptacel, Infanrix, Kinrix, Pediarix, Pentacel, and Quaracel. The Tdap vaccine segment comprises products such as Boostrix and Adacel. In terms of vaccine type, the pertussis vaccine market is classified into whole-cell vaccine and acellular vaccine. The acellular vaccine segment is highly used owing to less side effect. The acellular vaccine is about 71%–85% effective, whereas whole-cell vaccine is about 78% effective. In terms of age group, the pertussis vaccine market is classified into adult and pediatric. In terms of end-user, the market is classified into hospitals, clinics, and vaccination centers. Geographically, the pertussis vaccine market is classified into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.

North America dominates the pertussis vaccine market due to growth in number of geriatric population and increase in pertussis death rate in the U.S, which drive the pertussis vaccine market. In 2014, according to the CDC, 28,660 cases of pertussis were reported in the U.S. The North America market is followed by the Europe and Asia Pacific markets. Asia Pacific is expected to grow at a higher rate due to rapid population growth, increase in adoption for vaccination, and growth in prevalence of infectious disease. These factors are expected to fuel the pertussis vaccine market. In the Asia Pacific region, Thailand accounts for 99% in pertussis vaccine coverage, followed by Japan and China with 98% and 97%, respectively. Developing countries such as Brazil, South Africa, and Mexico are estimated to create good opportunity for the pertussis vaccine market growth attributing to rise in number of government and private health care insurance coverage, increase in health care expenditure, and growth in awareness among people.
This report aims to provide a comprehensive presentation of the global market for DTaP and Tdap Vaccines, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding DTaP and Tdap Vaccines. This report contains market size and forecasts of DTaP and Tdap Vaccines in global, including the following market information:
Global DTaP and Tdap Vaccines Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global DTaP and Tdap Vaccines Market Sales, 2018-2023, 2024-2029, (K Units)
Global top five DTaP and Tdap Vaccines companies in 2022 (%)
The global DTaP and Tdap Vaccines market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
DTaP Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of DTaP and Tdap Vaccines include Sanofi Pasteur, GlaxoSmithKline, Protein Sciences Corporation, Novartis AG, Seqirus, Merck Sharp & Dohme Corp, Astellas Pharma US, Inc, Pfizer Inc and Johnson & Johnson, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the DTaP and Tdap Vaccines manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global DTaP and Tdap Vaccines Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global DTaP and Tdap Vaccines Market Segment Percentages, by Type, 2022 (%)
DTaP
Td
Tdap
Global DTaP and Tdap Vaccines Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global DTaP and Tdap Vaccines Market Segment Percentages, by Application, 2022 (%)
Adult
Pediatric
Global DTaP and Tdap Vaccines Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global DTaP and Tdap Vaccines Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies DTaP and Tdap Vaccines revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies DTaP and Tdap Vaccines revenues share in global market, 2022 (%)
Key companies DTaP and Tdap Vaccines sales in global market, 2018-2023 (Estimated), (K Units)
Key companies DTaP and Tdap Vaccines sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Sanofi Pasteur
GlaxoSmithKline
Protein Sciences Corporation
Novartis AG
Seqirus
Merck Sharp & Dohme Corp
Astellas Pharma US, Inc
Pfizer Inc
Johnson & Johnson
Lanzhou Institute of Biological Products Co., Ltd
AstraZeneca
Emergent BioSolutions Inc
Outline of Major Chapters:
Chapter 1: Introduces the definition of DTaP and Tdap Vaccines, market overview.
Chapter 2: Global DTaP and Tdap Vaccines market size in revenue and volume.
Chapter 3: Detailed analysis of DTaP and Tdap Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of DTaP and Tdap Vaccines in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global DTaP and Tdap Vaccines capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.

❖ レポートの目次 ❖

1 Introduction to Research & Analysis Reports
1.1 DTaP and Tdap Vaccines Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global DTaP and Tdap Vaccines Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global DTaP and Tdap Vaccines Overall Market Size
2.1 Global DTaP and Tdap Vaccines Market Size: 2022 VS 2029
2.2 Global DTaP and Tdap Vaccines Revenue, Prospects & Forecasts: 2018-2029
2.3 Global DTaP and Tdap Vaccines Sales: 2018-2029
3 Company Landscape
3.1 Top DTaP and Tdap Vaccines Players in Global Market
3.2 Top Global DTaP and Tdap Vaccines Companies Ranked by Revenue
3.3 Global DTaP and Tdap Vaccines Revenue by Companies
3.4 Global DTaP and Tdap Vaccines Sales by Companies
3.5 Global DTaP and Tdap Vaccines Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 DTaP and Tdap Vaccines Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers DTaP and Tdap Vaccines Product Type
3.8 Tier 1, Tier 2 and Tier 3 DTaP and Tdap Vaccines Players in Global Market
3.8.1 List of Global Tier 1 DTaP and Tdap Vaccines Companies
3.8.2 List of Global Tier 2 and Tier 3 DTaP and Tdap Vaccines Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global DTaP and Tdap Vaccines Market Size Markets, 2022 & 2029
4.1.2 DTaP
4.1.3 Td
4.1.4 Tdap
4.2 By Type – Global DTaP and Tdap Vaccines Revenue & Forecasts
4.2.1 By Type – Global DTaP and Tdap Vaccines Revenue, 2018-2023
4.2.2 By Type – Global DTaP and Tdap Vaccines Revenue, 2024-2029
4.2.3 By Type – Global DTaP and Tdap Vaccines Revenue Market Share, 2018-2029
4.3 By Type – Global DTaP and Tdap Vaccines Sales & Forecasts
4.3.1 By Type – Global DTaP and Tdap Vaccines Sales, 2018-2023
4.3.2 By Type – Global DTaP and Tdap Vaccines Sales, 2024-2029
4.3.3 By Type – Global DTaP and Tdap Vaccines Sales Market Share, 2018-2029
4.4 By Type – Global DTaP and Tdap Vaccines Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global DTaP and Tdap Vaccines Market Size, 2022 & 2029
5.1.2 Adult
5.1.3 Pediatric
5.2 By Application – Global DTaP and Tdap Vaccines Revenue & Forecasts
5.2.1 By Application – Global DTaP and Tdap Vaccines Revenue, 2018-2023
5.2.2 By Application – Global DTaP and Tdap Vaccines Revenue, 2024-2029
5.2.3 By Application – Global DTaP and Tdap Vaccines Revenue Market Share, 2018-2029
5.3 By Application – Global DTaP and Tdap Vaccines Sales & Forecasts
5.3.1 By Application – Global DTaP and Tdap Vaccines Sales, 2018-2023
5.3.2 By Application – Global DTaP and Tdap Vaccines Sales, 2024-2029
5.3.3 By Application – Global DTaP and Tdap Vaccines Sales Market Share, 2018-2029
5.4 By Application – Global DTaP and Tdap Vaccines Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global DTaP and Tdap Vaccines Market Size, 2022 & 2029
6.2 By Region – Global DTaP and Tdap Vaccines Revenue & Forecasts
6.2.1 By Region – Global DTaP and Tdap Vaccines Revenue, 2018-2023
6.2.2 By Region – Global DTaP and Tdap Vaccines Revenue, 2024-2029
6.2.3 By Region – Global DTaP and Tdap Vaccines Revenue Market Share, 2018-2029
6.3 By Region – Global DTaP and Tdap Vaccines Sales & Forecasts
6.3.1 By Region – Global DTaP and Tdap Vaccines Sales, 2018-2023
6.3.2 By Region – Global DTaP and Tdap Vaccines Sales, 2024-2029
6.3.3 By Region – Global DTaP and Tdap Vaccines Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America DTaP and Tdap Vaccines Revenue, 2018-2029
6.4.2 By Country – North America DTaP and Tdap Vaccines Sales, 2018-2029
6.4.3 US DTaP and Tdap Vaccines Market Size, 2018-2029
6.4.4 Canada DTaP and Tdap Vaccines Market Size, 2018-2029
6.4.5 Mexico DTaP and Tdap Vaccines Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe DTaP and Tdap Vaccines Revenue, 2018-2029
6.5.2 By Country – Europe DTaP and Tdap Vaccines Sales, 2018-2029
6.5.3 Germany DTaP and Tdap Vaccines Market Size, 2018-2029
6.5.4 France DTaP and Tdap Vaccines Market Size, 2018-2029
6.5.5 U.K. DTaP and Tdap Vaccines Market Size, 2018-2029
6.5.6 Italy DTaP and Tdap Vaccines Market Size, 2018-2029
6.5.7 Russia DTaP and Tdap Vaccines Market Size, 2018-2029
6.5.8 Nordic Countries DTaP and Tdap Vaccines Market Size, 2018-2029
6.5.9 Benelux DTaP and Tdap Vaccines Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia DTaP and Tdap Vaccines Revenue, 2018-2029
6.6.2 By Region – Asia DTaP and Tdap Vaccines Sales, 2018-2029
6.6.3 China DTaP and Tdap Vaccines Market Size, 2018-2029
6.6.4 Japan DTaP and Tdap Vaccines Market Size, 2018-2029
6.6.5 South Korea DTaP and Tdap Vaccines Market Size, 2018-2029
6.6.6 Southeast Asia DTaP and Tdap Vaccines Market Size, 2018-2029
6.6.7 India DTaP and Tdap Vaccines Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America DTaP and Tdap Vaccines Revenue, 2018-2029
6.7.2 By Country – South America DTaP and Tdap Vaccines Sales, 2018-2029
6.7.3 Brazil DTaP and Tdap Vaccines Market Size, 2018-2029
6.7.4 Argentina DTaP and Tdap Vaccines Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa DTaP and Tdap Vaccines Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa DTaP and Tdap Vaccines Sales, 2018-2029
6.8.3 Turkey DTaP and Tdap Vaccines Market Size, 2018-2029
6.8.4 Israel DTaP and Tdap Vaccines Market Size, 2018-2029
6.8.5 Saudi Arabia DTaP and Tdap Vaccines Market Size, 2018-2029
6.8.6 UAE DTaP and Tdap Vaccines Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Sanofi Pasteur
7.1.1 Sanofi Pasteur Company Summary
7.1.2 Sanofi Pasteur Business Overview
7.1.3 Sanofi Pasteur DTaP and Tdap Vaccines Major Product Offerings
7.1.4 Sanofi Pasteur DTaP and Tdap Vaccines Sales and Revenue in Global (2018-2023)
7.1.5 Sanofi Pasteur Key News & Latest Developments
7.2 GlaxoSmithKline
7.2.1 GlaxoSmithKline Company Summary
7.2.2 GlaxoSmithKline Business Overview
7.2.3 GlaxoSmithKline DTaP and Tdap Vaccines Major Product Offerings
7.2.4 GlaxoSmithKline DTaP and Tdap Vaccines Sales and Revenue in Global (2018-2023)
7.2.5 GlaxoSmithKline Key News & Latest Developments
7.3 Protein Sciences Corporation
7.3.1 Protein Sciences Corporation Company Summary
7.3.2 Protein Sciences Corporation Business Overview
7.3.3 Protein Sciences Corporation DTaP and Tdap Vaccines Major Product Offerings
7.3.4 Protein Sciences Corporation DTaP and Tdap Vaccines Sales and Revenue in Global (2018-2023)
7.3.5 Protein Sciences Corporation Key News & Latest Developments
7.4 Novartis AG
7.4.1 Novartis AG Company Summary
7.4.2 Novartis AG Business Overview
7.4.3 Novartis AG DTaP and Tdap Vaccines Major Product Offerings
7.4.4 Novartis AG DTaP and Tdap Vaccines Sales and Revenue in Global (2018-2023)
7.4.5 Novartis AG Key News & Latest Developments
7.5 Seqirus
7.5.1 Seqirus Company Summary
7.5.2 Seqirus Business Overview
7.5.3 Seqirus DTaP and Tdap Vaccines Major Product Offerings
7.5.4 Seqirus DTaP and Tdap Vaccines Sales and Revenue in Global (2018-2023)
7.5.5 Seqirus Key News & Latest Developments
7.6 Merck Sharp & Dohme Corp
7.6.1 Merck Sharp & Dohme Corp Company Summary
7.6.2 Merck Sharp & Dohme Corp Business Overview
7.6.3 Merck Sharp & Dohme Corp DTaP and Tdap Vaccines Major Product Offerings
7.6.4 Merck Sharp & Dohme Corp DTaP and Tdap Vaccines Sales and Revenue in Global (2018-2023)
7.6.5 Merck Sharp & Dohme Corp Key News & Latest Developments
7.7 Astellas Pharma US, Inc
7.7.1 Astellas Pharma US, Inc Company Summary
7.7.2 Astellas Pharma US, Inc Business Overview
7.7.3 Astellas Pharma US, Inc DTaP and Tdap Vaccines Major Product Offerings
7.7.4 Astellas Pharma US, Inc DTaP and Tdap Vaccines Sales and Revenue in Global (2018-2023)
7.7.5 Astellas Pharma US, Inc Key News & Latest Developments
7.8 Pfizer Inc
7.8.1 Pfizer Inc Company Summary
7.8.2 Pfizer Inc Business Overview
7.8.3 Pfizer Inc DTaP and Tdap Vaccines Major Product Offerings
7.8.4 Pfizer Inc DTaP and Tdap Vaccines Sales and Revenue in Global (2018-2023)
7.8.5 Pfizer Inc Key News & Latest Developments
7.9 Johnson & Johnson
7.9.1 Johnson & Johnson Company Summary
7.9.2 Johnson & Johnson Business Overview
7.9.3 Johnson & Johnson DTaP and Tdap Vaccines Major Product Offerings
7.9.4 Johnson & Johnson DTaP and Tdap Vaccines Sales and Revenue in Global (2018-2023)
7.9.5 Johnson & Johnson Key News & Latest Developments
7.10 Lanzhou Institute of Biological Products Co., Ltd
7.10.1 Lanzhou Institute of Biological Products Co., Ltd Company Summary
7.10.2 Lanzhou Institute of Biological Products Co., Ltd Business Overview
7.10.3 Lanzhou Institute of Biological Products Co., Ltd DTaP and Tdap Vaccines Major Product Offerings
7.10.4 Lanzhou Institute of Biological Products Co., Ltd DTaP and Tdap Vaccines Sales and Revenue in Global (2018-2023)
7.10.5 Lanzhou Institute of Biological Products Co., Ltd Key News & Latest Developments
7.11 AstraZeneca
7.11.1 AstraZeneca Company Summary
7.11.2 AstraZeneca DTaP and Tdap Vaccines Business Overview
7.11.3 AstraZeneca DTaP and Tdap Vaccines Major Product Offerings
7.11.4 AstraZeneca DTaP and Tdap Vaccines Sales and Revenue in Global (2018-2023)
7.11.5 AstraZeneca Key News & Latest Developments
7.12 Emergent BioSolutions Inc
7.12.1 Emergent BioSolutions Inc Company Summary
7.12.2 Emergent BioSolutions Inc DTaP and Tdap Vaccines Business Overview
7.12.3 Emergent BioSolutions Inc DTaP and Tdap Vaccines Major Product Offerings
7.12.4 Emergent BioSolutions Inc DTaP and Tdap Vaccines Sales and Revenue in Global (2018-2023)
7.12.5 Emergent BioSolutions Inc Key News & Latest Developments
8 Global DTaP and Tdap Vaccines Production Capacity, Analysis
8.1 Global DTaP and Tdap Vaccines Production Capacity, 2018-2029
8.2 DTaP and Tdap Vaccines Production Capacity of Key Manufacturers in Global Market
8.3 Global DTaP and Tdap Vaccines Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 DTaP and Tdap Vaccines Supply Chain Analysis
10.1 DTaP and Tdap Vaccines Industry Value Chain
10.2 DTaP and Tdap Vaccines Upstream Market
10.3 DTaP and Tdap Vaccines Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 DTaP and Tdap Vaccines Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer

List of Tables
Table 1. Key Players of DTaP and Tdap Vaccines in Global Market
Table 2. Top DTaP and Tdap Vaccines Players in Global Market, Ranking by Revenue (2022)
Table 3. Global DTaP and Tdap Vaccines Revenue by Companies, (US$, Mn), 2018-2023
Table 4. Global DTaP and Tdap Vaccines Revenue Share by Companies, 2018-2023
Table 5. Global DTaP and Tdap Vaccines Sales by Companies, (K Units), 2018-2023
Table 6. Global DTaP and Tdap Vaccines Sales Share by Companies, 2018-2023
Table 7. Key Manufacturers DTaP and Tdap Vaccines Price (2018-2023) & (USD/Unit)
Table 8. Global Manufacturers DTaP and Tdap Vaccines Product Type
Table 9. List of Global Tier 1 DTaP and Tdap Vaccines Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 DTaP and Tdap Vaccines Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type – Global DTaP and Tdap Vaccines Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Global DTaP and Tdap Vaccines Revenue (US$, Mn), 2018-2023
Table 13. By Type - Global DTaP and Tdap Vaccines Revenue (US$, Mn), 2024-2029
Table 14. By Type - Global DTaP and Tdap Vaccines Sales (K Units), 2018-2023
Table 15. By Type - Global DTaP and Tdap Vaccines Sales (K Units), 2024-2029
Table 16. By Application – Global DTaP and Tdap Vaccines Revenue, (US$, Mn), 2022 & 2029
Table 17. By Application - Global DTaP and Tdap Vaccines Revenue (US$, Mn), 2018-2023
Table 18. By Application - Global DTaP and Tdap Vaccines Revenue (US$, Mn), 2024-2029
Table 19. By Application - Global DTaP and Tdap Vaccines Sales (K Units), 2018-2023
Table 20. By Application - Global DTaP and Tdap Vaccines Sales (K Units), 2024-2029
Table 21. By Region – Global DTaP and Tdap Vaccines Revenue, (US$, Mn), 2022 VS 2029
Table 22. By Region - Global DTaP and Tdap Vaccines Revenue (US$, Mn), 2018-2023
Table 23. By Region - Global DTaP and Tdap Vaccines Revenue (US$, Mn), 2024-2029
Table 24. By Region - Global DTaP and Tdap Vaccines Sales (K Units), 2018-2023
Table 25. By Region - Global DTaP and Tdap Vaccines Sales (K Units), 2024-2029
Table 26. By Country - North America DTaP and Tdap Vaccines Revenue, (US$, Mn), 2018-2023
Table 27. By Country - North America DTaP and Tdap Vaccines Revenue, (US$, Mn), 2024-2029
Table 28. By Country - North America DTaP and Tdap Vaccines Sales, (K Units), 2018-2023
Table 29. By Country - North America DTaP and Tdap Vaccines Sales, (K Units), 2024-2029
Table 30. By Country - Europe DTaP and Tdap Vaccines Revenue, (US$, Mn), 2018-2023
Table 31. By Country - Europe DTaP and Tdap Vaccines Revenue, (US$, Mn), 2024-2029
Table 32. By Country - Europe DTaP and Tdap Vaccines Sales, (K Units), 2018-2023
Table 33. By Country - Europe DTaP and Tdap Vaccines Sales, (K Units), 2024-2029
Table 34. By Region - Asia DTaP and Tdap Vaccines Revenue, (US$, Mn), 2018-2023
Table 35. By Region - Asia DTaP and Tdap Vaccines Revenue, (US$, Mn), 2024-2029
Table 36. By Region - Asia DTaP and Tdap Vaccines Sales, (K Units), 2018-2023
Table 37. By Region - Asia DTaP and Tdap Vaccines Sales, (K Units), 2024-2029
Table 38. By Country - South America DTaP and Tdap Vaccines Revenue, (US$, Mn), 2018-2023
Table 39. By Country - South America DTaP and Tdap Vaccines Revenue, (US$, Mn), 2024-2029
Table 40. By Country - South America DTaP and Tdap Vaccines Sales, (K Units), 2018-2023
Table 41. By Country - South America DTaP and Tdap Vaccines Sales, (K Units), 2024-2029
Table 42. By Country - Middle East & Africa DTaP and Tdap Vaccines Revenue, (US$, Mn), 2018-2023
Table 43. By Country - Middle East & Africa DTaP and Tdap Vaccines Revenue, (US$, Mn), 2024-2029
Table 44. By Country - Middle East & Africa DTaP and Tdap Vaccines Sales, (K Units), 2018-2023
Table 45. By Country - Middle East & Africa DTaP and Tdap Vaccines Sales, (K Units), 2024-2029
Table 46. Sanofi Pasteur Company Summary
Table 47. Sanofi Pasteur DTaP and Tdap Vaccines Product Offerings
Table 48. Sanofi Pasteur DTaP and Tdap Vaccines Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 49. Sanofi Pasteur Key News & Latest Developments
Table 50. GlaxoSmithKline Company Summary
Table 51. GlaxoSmithKline DTaP and Tdap Vaccines Product Offerings
Table 52. GlaxoSmithKline DTaP and Tdap Vaccines Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 53. GlaxoSmithKline Key News & Latest Developments
Table 54. Protein Sciences Corporation Company Summary
Table 55. Protein Sciences Corporation DTaP and Tdap Vaccines Product Offerings
Table 56. Protein Sciences Corporation DTaP and Tdap Vaccines Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 57. Protein Sciences Corporation Key News & Latest Developments
Table 58. Novartis AG Company Summary
Table 59. Novartis AG DTaP and Tdap Vaccines Product Offerings
Table 60. Novartis AG DTaP and Tdap Vaccines Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 61. Novartis AG Key News & Latest Developments
Table 62. Seqirus Company Summary
Table 63. Seqirus DTaP and Tdap Vaccines Product Offerings
Table 64. Seqirus DTaP and Tdap Vaccines Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 65. Seqirus Key News & Latest Developments
Table 66. Merck Sharp & Dohme Corp Company Summary
Table 67. Merck Sharp & Dohme Corp DTaP and Tdap Vaccines Product Offerings
Table 68. Merck Sharp & Dohme Corp DTaP and Tdap Vaccines Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 69. Merck Sharp & Dohme Corp Key News & Latest Developments
Table 70. Astellas Pharma US, Inc Company Summary
Table 71. Astellas Pharma US, Inc DTaP and Tdap Vaccines Product Offerings
Table 72. Astellas Pharma US, Inc DTaP and Tdap Vaccines Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 73. Astellas Pharma US, Inc Key News & Latest Developments
Table 74. Pfizer Inc Company Summary
Table 75. Pfizer Inc DTaP and Tdap Vaccines Product Offerings
Table 76. Pfizer Inc DTaP and Tdap Vaccines Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 77. Pfizer Inc Key News & Latest Developments
Table 78. Johnson & Johnson Company Summary
Table 79. Johnson & Johnson DTaP and Tdap Vaccines Product Offerings
Table 80. Johnson & Johnson DTaP and Tdap Vaccines Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 81. Johnson & Johnson Key News & Latest Developments
Table 82. Lanzhou Institute of Biological Products Co., Ltd Company Summary
Table 83. Lanzhou Institute of Biological Products Co., Ltd DTaP and Tdap Vaccines Product Offerings
Table 84. Lanzhou Institute of Biological Products Co., Ltd DTaP and Tdap Vaccines Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 85. Lanzhou Institute of Biological Products Co., Ltd Key News & Latest Developments
Table 86. AstraZeneca Company Summary
Table 87. AstraZeneca DTaP and Tdap Vaccines Product Offerings
Table 88. AstraZeneca DTaP and Tdap Vaccines Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 89. AstraZeneca Key News & Latest Developments
Table 90. Emergent BioSolutions Inc Company Summary
Table 91. Emergent BioSolutions Inc DTaP and Tdap Vaccines Product Offerings
Table 92. Emergent BioSolutions Inc DTaP and Tdap Vaccines Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 93. Emergent BioSolutions Inc Key News & Latest Developments
Table 94. DTaP and Tdap Vaccines Production Capacity (K Units) of Key Manufacturers in Global Market, 2021-2023 (K Units)
Table 95. Global DTaP and Tdap Vaccines Capacity Market Share of Key Manufacturers, 2021-2023
Table 96. Global DTaP and Tdap Vaccines Production by Region, 2018-2023 (K Units)
Table 97. Global DTaP and Tdap Vaccines Production by Region, 2024-2029 (K Units)
Table 98. DTaP and Tdap Vaccines Market Opportunities & Trends in Global Market
Table 99. DTaP and Tdap Vaccines Market Drivers in Global Market
Table 100. DTaP and Tdap Vaccines Market Restraints in Global Market
Table 101. DTaP and Tdap Vaccines Raw Materials
Table 102. DTaP and Tdap Vaccines Raw Materials Suppliers in Global Market
Table 103. Typical DTaP and Tdap Vaccines Downstream
Table 104. DTaP and Tdap Vaccines Downstream Clients in Global Market
Table 105. DTaP and Tdap Vaccines Distributors and Sales Agents in Global Market
List of Figures
Figure 1. DTaP and Tdap Vaccines Segment by Type in 2022
Figure 2. DTaP and Tdap Vaccines Segment by Application in 2022
Figure 3. Global DTaP and Tdap Vaccines Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global DTaP and Tdap Vaccines Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global DTaP and Tdap Vaccines Revenue, 2018-2029 (US$, Mn)
Figure 7. DTaP and Tdap Vaccines Sales in Global Market: 2018-2029 (K Units)
Figure 8. The Top 3 and 5 Players Market Share by DTaP and Tdap Vaccines Revenue in 2022
Figure 9. By Type - Global DTaP and Tdap Vaccines Revenue, (US$, Mn), 2022 & 2029
Figure 10. By Type - Global DTaP and Tdap Vaccines Revenue Market Share, 2018-2029
Figure 11. By Type - Global DTaP and Tdap Vaccines Sales Market Share, 2018-2029
Figure 12. By Type - Global DTaP and Tdap Vaccines Price (USD/Unit), 2018-2029
Figure 13. By Application - Global DTaP and Tdap Vaccines Revenue, (US$, Mn), 2022 & 2029
Figure 14. By Application - Global DTaP and Tdap Vaccines Revenue Market Share, 2018-2029
Figure 15. By Application - Global DTaP and Tdap Vaccines Sales Market Share, 2018-2029
Figure 16. By Application - Global DTaP and Tdap Vaccines Price (USD/Unit), 2018-2029
Figure 17. By Region - Global DTaP and Tdap Vaccines Revenue, (US$, Mn), 2022 & 2029
Figure 18. By Region - Global DTaP and Tdap Vaccines Revenue Market Share, 2018 VS 2022 VS 2029
Figure 19. By Region - Global DTaP and Tdap Vaccines Revenue Market Share, 2018-2029
Figure 20. By Region - Global DTaP and Tdap Vaccines Sales Market Share, 2018-2029
Figure 21. By Country - North America DTaP and Tdap Vaccines Revenue Market Share, 2018-2029
Figure 22. By Country - North America DTaP and Tdap Vaccines Sales Market Share, 2018-2029
Figure 23. US DTaP and Tdap Vaccines Revenue, (US$, Mn), 2018-2029
Figure 24. Canada DTaP and Tdap Vaccines Revenue, (US$, Mn), 2018-2029
Figure 25. Mexico DTaP and Tdap Vaccines Revenue, (US$, Mn), 2018-2029
Figure 26. By Country - Europe DTaP and Tdap Vaccines Revenue Market Share, 2018-2029
Figure 27. By Country - Europe DTaP and Tdap Vaccines Sales Market Share, 2018-2029
Figure 28. Germany DTaP and Tdap Vaccines Revenue, (US$, Mn), 2018-2029
Figure 29. France DTaP and Tdap Vaccines Revenue, (US$, Mn), 2018-2029
Figure 30. U.K. DTaP and Tdap Vaccines Revenue, (US$, Mn), 2018-2029
Figure 31. Italy DTaP and Tdap Vaccines Revenue, (US$, Mn), 2018-2029
Figure 32. Russia DTaP and Tdap Vaccines Revenue, (US$, Mn), 2018-2029
Figure 33. Nordic Countries DTaP and Tdap Vaccines Revenue, (US$, Mn), 2018-2029
Figure 34. Benelux DTaP and Tdap Vaccines Revenue, (US$, Mn), 2018-2029
Figure 35. By Region - Asia DTaP and Tdap Vaccines Revenue Market Share, 2018-2029
Figure 36. By Region - Asia DTaP and Tdap Vaccines Sales Market Share, 2018-2029
Figure 37. China DTaP and Tdap Vaccines Revenue, (US$, Mn), 2018-2029
Figure 38. Japan DTaP and Tdap Vaccines Revenue, (US$, Mn), 2018-2029
Figure 39. South Korea DTaP and Tdap Vaccines Revenue, (US$, Mn), 2018-2029
Figure 40. Southeast Asia DTaP and Tdap Vaccines Revenue, (US$, Mn), 2018-2029
Figure 41. India DTaP and Tdap Vaccines Revenue, (US$, Mn), 2018-2029
Figure 42. By Country - South America DTaP and Tdap Vaccines Revenue Market Share, 2018-2029
Figure 43. By Country - South America DTaP and Tdap Vaccines Sales Market Share, 2018-2029
Figure 44. Brazil DTaP and Tdap Vaccines Revenue, (US$, Mn), 2018-2029
Figure 45. Argentina DTaP and Tdap Vaccines Revenue, (US$, Mn), 2018-2029
Figure 46. By Country - Middle East & Africa DTaP and Tdap Vaccines Revenue Market Share, 2018-2029
Figure 47. By Country - Middle East & Africa DTaP and Tdap Vaccines Sales Market Share, 2018-2029
Figure 48. Turkey DTaP and Tdap Vaccines Revenue, (US$, Mn), 2018-2029
Figure 49. Israel DTaP and Tdap Vaccines Revenue, (US$, Mn), 2018-2029
Figure 50. Saudi Arabia DTaP and Tdap Vaccines Revenue, (US$, Mn), 2018-2029
Figure 51. UAE DTaP and Tdap Vaccines Revenue, (US$, Mn), 2018-2029
Figure 52. Global DTaP and Tdap Vaccines Production Capacity (K Units), 2018-2029
Figure 53. The Percentage of Production DTaP and Tdap Vaccines by Region, 2022 VS 2029
Figure 54. DTaP and Tdap Vaccines Industry Value Chain
Figure 55. Marketing Channels


★調査レポート[世界のDTaP＆Tdapワクチン市場予測2023-2029：DTaP、Td、Tdap] (コード：MMG23LY8501)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界のDTaP＆Tdapワクチン市場予測2023-2029：DTaP、Td、Tdap]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 世界のDPTワクチン接種市場2022年：DTaP、Tdap、DTwP
  • 世界の破傷風ワクチン市場予測2023-2029：ジフテリア・破傷風（DT）ワクチン、ジフテリア・破傷風・百日咳（百日咳）（DTaP）ワクチン、破傷風・ジフテリア（Td）ワクチン、破傷風・ジフテリア・百日咳（Tdap）ワクチン
  • 世界のポリオワクチン市場予測2023-2029：IPV、OPV
  • 世界の経口コレラ生ワクチン市場予測2023-2029：Dukoral、Shanchol、Vaxchora、その他
  • 世界の豚流行性下痢ワクチン市場予測2023-2029：生ワクチン、死菌ワクチン

    • ◆H&Iグローバルリサーチのお客様（例）◆